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Abstract
Common genetic variants contribute to the observed variation in breast cancer risk for BRCA2 mutation carriers; those
known to date have all been found through population-based genome-wide association studies (GWAS). To
comprehensively identify breast cancer risk modifying loci for BRCA2 mutation carriers, we conducted a deep replication
of an ongoing GWAS discovery study. Using the ranked P-values of the breast cancer associations with the imputed
genotype of 1.4 M SNPs, 19,029 SNPs were selected and designed for inclusion on a custom Illumina array that included a
total of 211,155 SNPs as part of a multi-consortial project. DNA samples from 3,881 breast cancer affected and 4,330
unaffected BRCA2 mutation carriers from 47 studies belonging to the Consortium of Investigators of Modifiers of BRCA1/2
were genotyped and available for analysis. We replicated previously reported breast cancer susceptibility alleles in these
BRCA2 mutation carriers and for several regions (including FGFR2, MAP3K1, CDKN2A/B, and PTHLH) identified SNPs that have
stronger evidence of association than those previously published. We also identified a novel susceptibility allele at 6p24 that
was inversely associated with risk in BRCA2 mutation carriers (rs9348512; per allele HR = 0.85, 95% CI 0.80–0.90,
P = 3.961028). This SNP was not associated with breast cancer risk either in the general population or in BRCA1 mutation
carriers. The locus lies within a region containing TFAP2A, which encodes a transcriptional activation protein that interacts
with several tumor suppressor genes. This report identifies the first breast cancer risk locus specific to a BRCA2 mutation
background. This comprehensive update of novel and previously reported breast cancer susceptibility loci contributes to
the establishment of a panel of SNPs that modify breast cancer risk in BRCA2 mutation carriers. This panel may have clinical
utility for women with BRCA2 mutations weighing options for medical prevention of breast cancer.
GWAS of BRCA2 Mutation Carriers
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Introduction
The lifetime risk of breast cancer associated with carrying a
BRCA2 mutation varies from 40 to 84% [1]. To determine
whether common genetic variants modify breast cancer risk for
BRCA2 mutation carriers, we previously conducted a GWAS of
BRCA2 mutation carriers from the Consortium of Investigators of
Modifiers of BRCA1/2 (CIMBA) [2]. Using the Affymetrix 6.0
platform, the discovery stage results were based on 899 young
(,40 years) affected and 804 unaffected carriers of European
ancestry. In a rapid replication stage wherein 85 discovery stage
SNPs with the smallest P-values were genotyped in 2,486
additional BRCA2 mutation carriers, only published loci associated
with breast cancer risk in the general population, including FGFR2
(10q26; rs2981575; P = 1.261028), were associated with breast
cancer risk at the genome-wide significance level among BRCA2
GWAS of BRCA2 Mutation Carriers
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mutation carriers. Two other loci, in ZNF365 (rs16917302) on
10q21 and a locus on 20q13 (rs311499), were also associated with
breast cancer risk in BRCA2 mutation carriers with P-values,1024
(P = 3.861025 and 6.661025, respectively). A nearby SNP in
ZNF365 was also associated with breast cancer risk in a study of
unselected cases [3] and in a study of mammographic density [4].
Additional follow-up replicated the findings for rs16917302, but
not rs311499 [5] in a larger set of BRCA2 mutation carriers. To
seek additional breast cancer risk modifying loci for BRCA2
mutation carriers, we conducted an extended replication of the
GWAS discovery results in a larger set of BRCA2 mutation carriers
in CIMBA, which represents the largest, international collection of
BRCA2 mutation carriers.
Materials and Methods
Ethics statement
Each of the host institutions (Table S1) recruited under
ethically-approved protocols. Written informed consent was
obtained from all subjects.
Study subjects
The majority of BRCA2 mutation carriers were recruited
through cancer genetics clinics and some came from population
or community-based studies. Studies contributing DNA samples to
these research efforts were members of the Consortium of
Investigators of Modifiers of BRCA1/2 (CIMBA) with the
exception of one study (NICCC). Eligible subjects were women
of European descent who carried a pathogenic BRCA2 mutation,
had complete phenotype information, and were at least 18 years of
age. Harmonized phenotypic data included year of birth, age at
cancer diagnosis, age at bilateral prophylactic mastectomy and
oophorectomy, age at interview or last follow-up, BRCA2 mutation
description, self-reported ethnicity, and breast cancer estrogen
receptor status.
GWAS discovery stage samples. Details of these samples
have been described previously [2]. Data from 899 young (,40
years) affected and 804 older (.40 years) unaffected carriers of
European ancestry from 14 countries were used to select SNPs for
inclusion on the iCOGS array.
Samples genotyped in the extended replication
set. Forty-seven studies from 24 different countries (including
two East-Asian countries) provided DNA from a total of 10,048
BRCA2 mutations carriers. All eligible samples were genotyped
using COGs, including those from the discovery stage.
Genotyping and quality control
BRCA2 SNP selection for inclusion on iCOGS. The
Collaborative Oncological Gene-Environment Study (COGS)
consortium developed a custom genotyping array (referred to as
the iCOGS array) to provide efficient genotyping of common and
rare genetic variants to identify novel loci that are associated with
risk of breast, ovarian, and prostate cancers as well as to fine-map
known cancer susceptibility loci. SNPs were selected for inclusion
on iCOGS separately by each participating consortium: Breast
Cancer Association Consortium (BCAC) [6], Ovarian Cancer
Association Consortium (OCAC) [7], Prostate Cancer Association
Group to Investigate Cancer Associated Alterations in the
Genome (PRACTICAL) [8], and CIMBA. SNP lists from a
BRCA1 GWAS and SNPs in candidate regions were used together
with the BRCA2 GWAS lists to generate a ranked CIMBA SNP list
that included SNPs with the following nominal proportions: 55.5%
from the BRCA1 GWAS, 41.6% from the BRCA2 GWAS and fine
mapping, 2.9% for CIMBA candidate SNPs. Each consortium was
given a share of the array: nominally 25% of the SNPs each for
BCAC, PRACTICAL and OCAC; 17.5% for CIMBA; and 7.5%
for SNPs from commonly researched pathways (e.g., inflamma-
tion). For the CIMBA BRCA2 GWAS, we used the iCOGS array
as the platform to genotype the extended replication set of the
discovery GWAS stage [2]. SNPs were selected on the basis of the
strength of their associations with breast cancer risk in the
discovery stage [2], using imputed genotype data for 1.4 M SNPs
identified through CEU+TSI samples on HapMap3, release 2. A
ranked list of SNPs was based on the 1-df trend test statistic, after
excluding highly correlated SNPs (r2.0.4). The final list included
the 39,015 SNPs with the smallest p-values. An additional set of
SNPs were selected for fine mapping of the regions surrounding
the SNPs found to be associated with breast cancer in the
discovery GWAS stage: rs16917302 on 10q21 and rs311499 on
20q13, including SNPs with a MAF .0.05 located 500 kb in both
directions of the SNP, based on HapMap 2 data. The final
combined list of SNPs for the iCOGS array comprised 220,123
SNPs. Of these, 211,155 were successfully manufactured onto the
array. The present analyses are based on the 19,029 SNPs selected
on the basis of BRCA2 GWAS and fine mapping that were
included on the iCOGS array.
Genotyping. The genotyping was performed on DNA
samples from 10,048 BRCA2 mutation carriers at the McGill
University and Ge´nome Que´bec Innovation Centre (Montreal,
Canada). As a quality control measure, each plate included DNA
samples from six individuals who were members of two CEPH
trios. Some plates also contained three duplicate pairs of quality
control samples. Genotypes were called using GenCall [9]. Initial
calling was based on a cluster file generated using 270 samples
from Hapmap2. To generate the final calls, we first selected a
subset of 3,018 individuals, including samples from each of the
genotyping centers in the iCOGS project, each of the participating
Author Summary
Women who carry BRCA2 mutations have an increased risk
of breast cancer that varies widely. To identify common
genetic variants that modify the breast cancer risk
associated with BRCA2 mutations, we have built upon
our previous work in which we examined genetic variants
across the genome in relation to breast cancer risk among
BRCA2 mutation carriers. Using a custom genotyping
platform with 211,155 genetic variants known as single
nucleotide polymorphisms (SNPs), we genotyped 3,881
women who had breast cancer and 4,330 women without
breast cancer, which represents the largest possible,
international collection of BRCA2 mutation carriers. We
identified that a SNP located at 6p24 in the genome was
associated with lower risk of breast cancer. Importantly,
this SNP was not associated with breast cancer in BRCA1
mutation carriers or in a general population of women,
indicating that the breast cancer association with this SNP
might be specific to BRCA2 mutation carriers. Combining
this BRCA2-specific SNP with 13 other breast cancer risk
SNPs also known to modify risk in BRCA2 mutation carriers,
we were able to derive a risk prediction model that could
be useful in helping women with BRCA2 mutations weigh
their risk-reduction strategy options.
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consortia, and each major ethnicity. Only plates with a consistent
high call rate in the initial calling were used. We also included 380
samples of European, African, and Asian ethnicity genotyped as
part of the Hapmap and 1000 Genomes project, and 160 samples
that were known positive controls for rare variants on the array.
This subset was used to generate a cluster file that was then applied
to call the genotypes for the remaining samples.
Quality control of SNPs. Of the 211,155 SNPs on the
iCOGS array, we excluded SNPs for the following reasons (Table
S2): on the Y-chromosome, call rate ,95%, deviations from
Hardy-Weinberg equilibrium (P,1027) using a stratified 1-d.f. test
[10], and monomorphic. SNPs that gave discrepant genotypes
among known duplicates were also excluded. After quality control
filtering, 200,908 SNPs were available for analysis (Table S2);
18,086 of which were selected on the basis of the discovery BRCA2
GWAS [2]. Cluster plots of all reported SNPs were inspected
manually for quality (Figure S1).
Description of imputation. Genotypes for SNPs identified
through the 1000 Genomes Phase I data (released Jan 2012) [11]
were imputed using all SNPs on the iCOGS chip in a region of
500 kb around the novel modifier locus at 6p24. The boundaries
were determined according to the linkage disequilibrium (LD)
structure in the region based on HapMap data. The imputation
was carried out using IMPUTE 2.2 [12]. SNPs with imputation
information/accuracy r2,0.30 were excluded in the analyses.
Quality control of DNA samples. Of 10,048 genotyped
samples (Table S2), 742 were excluded because they did not meet
the phenotypic eligibility criteria or had self-reported non-CEU
ethnicity. Samples were then excluded for the following reasons:
not female (XXY, XY), call rate,95%, low or high heterozygosity
(P,1026), discordant genotypes from previous CIMBA genotyp-
ing efforts, or discordant duplicate samples. For duplicates with
concordant phenotypic data, or in cases of cryptic monozygotic
twins, only one of the samples was included. Cryptic duplicates for
which phenotypic data indicated different individuals were all
excluded. Samples of non-European ancestry were identified using
multi-dimensional scaling, after combining the BRCA2 mutation
carrier samples with the HapMap2 CEU, CHB, JPT and YRI
samples using a set of 37,120 uncorrelated SNPs from the iCOGS
array. Samples with .19% non-European ancestry were excluded
(Figure S2). A total of 4,330 affected and 3,881 unaffected BRCA2
mutation carrier women of European ancestry from 42 studies
remained in the analysis (Table S1), including 3,234 breast cancer
cases and 3,490 unaffected carriers that were not in the discovery
set.
BRCA1 and BCAC samples. Details of the sample collec-
tion, genotyping and quality control process for the BRCA1 and
BCAC samples, are reported elsewhere [13,14].
Statistical methods
The associations between genotype and breast cancer risk were
analyzed within a retrospective cohort framework with time to
breast cancer diagnosis as the outcome [15]. Each BRCA2 carrier
was followed until the first event: breast or ovarian cancer
diagnosis, bilateral prophylactic mastectomy, or age at last
observation. Only those with a breast cancer diagnosis were
considered as cases in the analysis. The majority of mutation
carriers were recruited through genetic counseling centers where
genetic testing is targeted at women diagnosed with breast or
ovarian cancer and in particular to those diagnosed with breast
cancer at a young age. Therefore, these women are more likely to
be sampled compared to unaffected mutation carriers or carriers
diagnosed with the disease at older ages. As a consequence,
sampling was not random with respect to disease phenotype and
standard methods of survival analysis (such as Cox regression) may
lead to biased estimates of the associations [16]. We therefore
conducted the analysis by modelling the retrospective likelihood of
the observed genotypes conditional on the disease phenotypes.
This has been shown to provide unbiased estimates of the
associations [15]. The implementation of the retrospective
likelihoods has been described in detail elsewhere [15,17]. The
associations between genotype and breast cancer risk were assessed
using the 1degree of freedom score test statistic based on the
retrospective likelihood [15]. In order to account for non-
independence between relatives, an adjusted version of the score
test was used in which the variance of the score was derived taking
into account the correlation between the genotypes [18]. P-values
were not adjusted using genomic control because there was little
evidence of inflation. Inflation was assessed using the genomic
inflation factor, l. Since this estimate is dependent on sample size,
we also calculated l adjusted to 1000 affected and 1000 unaffected
samples. Per-allele and genotype-specific hazard-ratios (HR) and
95% confidence intervals (CI) were estimated by maximizing the
retrospective likelihood. Calendar-year and cohort-specific breast
cancer incidences for BRCA2 were used [1]. All analyses were
stratified by country of residence. The USA and Canada strata
were further subdivided by self-reported Ashkenazi Jewish
ancestry. The assumption of proportional hazards was assessed
by fitting a model that included a genotype-by-age interaction
term. Between-country heterogeneity was assessed by comparing
the results of the main analysis to a model with country-specific
log-HRs. A possible survival bias due to inclusion of prevalent
cases was evaluated by re-fitting the model after excluding affected
carriers that were diagnosed $5 years prior to study recruitment.
The associations between genotypes and tumor subtypes were
evaluated using an extension of the retrospective likelihood
approach that models the association with two or more subtypes
simultaneously [19]. To investigate whether any of the significant
SNPs were associated with ovarian cancer risk for BRCA2
mutation carriers and whether the inclusion of ovarian cancer
patients as unaffected subjects biased our results, we also analyzed
the data within a competing risks framework and estimated HR
simultaneously for breast and ovarian cancer using the methods
described elsewhere [15]. Analyses were carried out in R using the
GenABEL libraries [20] and custom-written software. The
retrospective likelihood was modeled in the pedigree-analysis
software MENDEL [21], as described in detail elsewhere [15].
TCGA analysis. Affymetrix SNP 6.0 genotype calls for
normal (non-tumor) breast DNA were downloaded for all
available individuals from The Cancer Genome Atlas in Septem-
ber 2011. Analyses were limited to the 401 individuals of
European ancestry based on principal component analysis.
Expression levels in breast tumor tissue were adjusted for the top
two principal components, age, gender (there are some male breast
cancer cases in TCGA), and average copy number across the gene
in the tumor. Linear regression was then used to test for
association between the SNP and the adjusted gene expression
level for all genes within one megabase.
Gene set enrichment analysis. To investigate enrichment
of genes associated with breast cancer risk, the gene-set
enrichment approach was implemented using Versatile Gene-
based Association Study [22] based on the ranked P-values from
retrospective likelihood analysis. Association List Go Annotator
was also used to prioritize gene pathways using functional
annotation from gene ontology (GO) [23] to increase the power
to detect association to a pathway, as opposed to individual genes
in the pathway. Both analyses were corrected for LD between
SNPs, variable gene size, and interdependence of GO categories,
GWAS of BRCA2 Mutation Carriers
PLOS Genetics | www.plosgenetics.org 6 March 2013 | Volume 9 | Issue 3 | e1003173
where applicable, based on imputation. 100,000 Monte Carlo
simulations were performed in VEGAS and 5000 replicate gene
lists using random sampling of SNPs and 5000 replicate studies
(sampling with replacement) were performed to estimate P-values.
Predicted absolute breast cancer risks by combined SNP
profile. We estimated the absolute risks of developing breast
cancer based on the joint distribution of SNPs associated with
breast cancer for BRCA2 mutation carriers. The methods have
been described elsewhere [24]. To construct the SNP profiles, we
considered the single SNP from each region with the strongest
evidence of association in the present dataset. We included all loci
that had previously been found to be associated with breast cancer
risk through GWAS in the general population and demonstrated
associations with breast cancer risk for BRCA2 mutation carriers,
and loci that had GWAS level of significance in the current study.
We assumed that all loci in the profile were independent (i.e. they
interact multiplicatively on BRCA2 breast cancer risk). Genotype
frequencies were obtained under the assumption of Hardy-
Weinberg Equilibrium. For each SNP, the effect of each allele
was assumed to be consistent with a multiplicative model (log-
additive). We assumed that the average, age-specific breast cancer
incidences, over all associated loci, agreed with published breast
cancer risk estimates for BRCA2 mutation carriers [1].
Results
The genomic inflation factor (l) based on the 18,086 BRCA2
GWAS SNPs in the 6,724 BRCA2 mutation carriers who were not
used in the SNP discovery set was 1.034 (l adjusted to 1000
affected and 1000 unaffected: 1.010, Figure S3). Multiple variants
were associated with breast cancer risk in the combined discovery
and replication datasets (Figure S4). SNPs in three independent
regions had P-values,561028; one was a region not previously
associated with breast cancer.
The most significant associations were observed for known
breast cancer susceptibility regions, rs2420946 (per allele
P = 2610214) in FGFR2 and rs3803662 (P = 5.4610211) near
TOX3 (Table 1). Breast cancer risk associations with other SNPs
reported previously for BRCA2 mutation carriers are summarized
in Table 1. In this larger set of BRCA2 mutation carriers, we also
identified novel SNPs in the 12p11 (PTHLH), 5q11 (MAP3K1), and
9p21 (CDKN2A/B) regions with smaller P-values for association
than those of previously reported SNPs. These novel SNPs were
not correlated with the previously reported SNPs (r2,0.14). For
one of the novel SNPs identified in the discovery GWAS [2],
ZNF365 rs16917302, there was weak evidence of association with
breast cancer risk (P = 0.01); however, an uncorrelated SNP,
rs17221319 (r2,0.01), 54 kb upstream of rs16917302 had
stronger evidence of association (P = 661023).
One SNP, rs9348512 at 6p24 not known to be associated with
breast cancer, had a combined P-value of association of 3.961028
amongst all BRCA2 samples (Table 2), with strong evidence of
replication in the set of BRCA2 samples that were not used in the
discovery stage (P = 5.261025). The minor allele of rs9348512
(MAF = 0.35) was associated with a 15% decreased risk of breast
cancer among BRCA2 mutation carriers (per allele HR = 0.85,
95% CI 0.80–0.90) with no evidence of between-country
heterogeneity (P = 0.78, Figure S5). None of the genotyped
(n = 68) or imputed (n = 3,507) SNPs in that region showed a
stronger association with risk (Figure 1; Table S3), but there were
40 SNPs with P,1024 (pairwise r2.0.38 with rs9348512, with the
exception of rs11526201 for which r2 = 0.01, Table S3). The
association with rs9348512 did not differ by 6174delT mutation
status (P for difference = 0.33), age (P = 0.39), or estrogen receptor
(ER) status of the breast tumor (P = 0.41). Exclusion of prevalent
breast cancer cases (n = 1,752) produced results (HR = 0.83, 95%
CI 0.77–0.89, P = 3.4061027) consistent with those for all cases.
SNPs in two additional regions had P-values,1025 for breast
cancer risk associations for BRCA2 mutation carriers (Table 2).
The magnitude of associations for both SNPs was similar in the
discovery and second stage samples. In the combined analysis of
all samples, the minor allele of rs619373, located in FGF13
(Xq26.3), was associated with higher breast cancer risk
(HR = 1.30, 95% CI 1.17–1.45, P = 3.161026). The minor allele
of rs184577, located in CYP1B1-AS1 (2p22–p21), was associated
with lower breast cancer risk (HR = 0.85, 95% CI 0.79–0.91,
P = 3.661026). These findings were consistent across countries (P
for heterogeneity between country strata = 0.39 and P = 0.30,
respectively; Figure S6). There was no evidence that the HR
estimates for rs619373 and rs184577 change with age of the
BRCA2 mutation carriers (P for the genotype-age interac-
tion = 0.80 and P = 0.40, respectively) and no evidence of survival
bias for either SNP (rs619373: HR = 1.35, 95% CI 1.20–1.53,
P = 1.561026 and rs184577: HR = 0.86, 95% CI 0.79–0.93,
P = 2.061024, after excluding prevalent cases). The estimates for
risk of ER-negative and ER-positive breast cancer were not
significantly different (P for heterogeneity between tumor sub-
types = 0.79 and 0.67, respectively). When associations were
evaluated under a competing risks model, there was no evidence
of association with ovarian cancer risk for SNPs rs9348512 at
6p24, rs619373 in FGF13 or rs184577 at 2p22 and the breast
cancer associations were virtually unchanged (Table S4).
Gene set enrichment analysis confirmed that strong associations
exist for known breast cancer susceptibility loci and the novel loci
identified here (gene-based P,161025). The pathways most
strongly associated with breast cancer risk that contained
statistically significant SNPs included those related to ATP
binding, organ morphogenesis, and several nucleotide bindings
(pathway-based P,0.05).
To begin to determine the functional effect of rs9348512, we
examined associations of expression levels of any nearby gene in
breast tumors with the minor A allele. Using data from The
Cancer Genome Atlas, we found that the A allele of rs9348512
was strongly associated with mRNA levels of GCNT2 in breast
tumors (p= 7.361025).
The hazard ratios for the percentiles of the combined genotype
distribution of loci associated with breast cancer risk in BRCA2
mutation carriers were translated into absolute breast cancer risks
under the assumption that SNPs interact multiplicatively. Based
on our results for SNPs in FGFR2, TOX3, 12p11, 5q11, CDKN2A/
B, LSP1, 8q24, ESR1, ZNF365, 3p24, 12q24, 5p12, 11q13 and also
the 6p24 locus, the 5% of the BRCA2 mutation carriers at lowest
risk were predicted to have breast cancer risks by age 80 in the
range of 21–47% compared to 83–100% for the 5% of mutation
carriers at highest risk on the basis of the combined SNP profile
distribution (Figure 2). The breast cancer risk by age 50 was
predicted to be 4–11% for the 5% of the carriers at lowest risk
compared to 29–81% for the 5% at highest risk.
Discussion
In the largest assemblage of BRCA2 mutation carriers, we
identified a novel locus at 6q24 that is associated with breast
cancer risk, and noted two potential SNPs of interest at Xq26 and
2p22. We also replicated associations with known breast cancer
susceptibility SNPs previously reported in the general population
and in BRCA2 mutation carriers. For the 12p11 (PTHLH), 5q11
(MAP3K1), and 9p21 (CDKN2A/B), we found uncorrelated SNPs
GWAS of BRCA2 Mutation Carriers
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that had stronger associations than the originally identified SNP in
the breast cancer susceptibility region that should be replicated in
the general population. In BRCA2 mutation carriers, evidence for
a breast cancer association with genetic variants in PTHLH has
been restricted previously to ER-negative tumors [25]; however,
the novel susceptibility variant we reported here was associated
with risk of ER+ and ER- breast cancer.
The novel SNP rs9348512 (6p24) is located in a region with no
known genes (Figure 1). C6orf218, a gene encoding a hypothetical
protein LOC221718, and a possible tumor suppressor gene,
TFAP2A, are within 100 kb of rs9348512. TFAP2A encodes the
AP-2a transcription factor that is normally expressed in breast
ductal epithelium nuclei, with progressive expression loss from
normal, to ductal carcinoma in situ, to invasive cancer [26,27]. AP-
2a also acts as a tumor suppressor via negative regulation of MYC
[28] and augmented p53-dependent transcription [29]. However,
the minor allele of rs9348512 was not associated with gene
expression changes of TFAP2A in breast cancer tissues in The
Cancer Genome Atlas (TCGA) data; this analysis might not be
informative since expression of TFAP2A in invasive breast tissue is
low [26,27]. Using the TCGA data and a 1 Mb window,
expression changes with genotypes of rs9348512 were observed
for GCNT2, the gene encoding the enzyme for the blood group I
antigen glucosaminyl (N-acetyl) transferase 2. GCNT2, recently
found to be overexpressed in highly metastatic breast cancer cell
lines [30] and basal-like breast cancer [31], interacts with TGF-b
to promote epithelial-to-mesenchymal transition, enhancing the
metastatic potential of breast cancer [31]. An assessment of
alterations in expression patterns in normal breast tissue from
BRCA2 mutation carriers by genotype are needed to further
evaluate the functional implications of rs9348512 in the breast
tumorigenesis of BRCA2 mutation carriers.
To determine whether the breast cancer association with
rs9348512 was limited to BRCA2 mutation carriers, we compared
results to those in the general population genotyped by BCAC and
to BRCA1 mutation carriers in CIMBA. No evidence of an
associations between rs9348512 and breast cancer risk was
observed in the general population (OR = 1.00, 95% CI 0.98–
1.02, P = 0.74) [14], nor in BRCA1 mutation carriers (HR = 0.99,
95% CI 0.94–1.04, P = 0.75) [13]. Stratifying cases by ER status,
there was no association observed with ER-subtypes in either the
general population or among BRCA1 mutation carriers (BCAC:
ER positive P = 0.89 and ER negative P = 0.60; CIMBA BRCA1:
P = 0.49 and P = 0.99, respectively). For the two SNPs associated
with breast cancer with P,1025, neither rs619373, located in
FGF13 (Xq26.3), nor rs184577, located in CYP1B1-AS1 (2p22-
p21), was associated with breast cancer risk in the general
population [14] or among BRCA1 mutation carriers [13]. The
narrow CIs for the overall associations in the general population
and in BRCA1 mutation carriers rule out associations of magnitude
similar to those observed for BRCA2 mutation carriers. The
consistency of the association in the discovery and replication
stages and by country, the strong quality control measures and
filters, and the clear cluster plot for rs9348512 suggest that our
results constitute the discovery of a novel breast cancer suscepti-
bility locus specific to BRCA2 mutation carriers rather than a false
positive finding. Replicating this SNP in an even larger population
of BRCA2 mutation carriers would be ideal, but not currently
Figure 1. Associations between SNPs in the region surrounding rs9348512 on chromosome 6 and breast cancer risk. Results based on
imputed and observed genotypes. The blue spikes indicate the recombination rate at each position. Genotyped SNPs are represented by diamonds
and imputed SNPs are represented by squares. Color saturation indicates the degree of correlation with the SNP rs9348512.
doi:10.1371/journal.pgen.1003173.g001
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possible because we know of no investigators with appropriate data
and germline DNA from BRCA2 mutation carriers who did not
contribute their mutation carriers to iCOGS. However, CIMBA
studies continue to recruit individuals into the consortium.
rs9348512 (6p24) is the first example of a common susceptibility
variant identified through GWAS that modifies breast cancer risk
specifically in BRCA2 mutation carriers. Previously reported
BRCA2-modifying alleles for breast cancer, including those in
FGFR2, TOX3, MAP3K1, LSP1, 2q35, SLC4A7, 5p12, 1p11.2,
ZNF365, and 19p13.1 (ER-negative only) [18,32,33], are also
associated with breast cancer risk in the general population and/or
BRCA1 mutation carriers. Knowledge of the 6p24 locus might
provide further insights into the biology of breast cancer
development in BRCA2 mutation carriers. Additional variants
that are specific modifiers of breast cancer risk in BRCA2 carriers
may yet be discovered; their detection would require assembling
larger samples of BRCA2 mutation carriers in the future.
While individually each of the SNPs associated with breast
cancer in BRCA2 mutation carriers are unlikely to be used to guide
breast cancer screening and risk-reducing management strategies,
the combined effect of the general and BRCA2-specific breast
cancer susceptibility SNPs might be used to tailor manage subsets
of BRCA2 mutation carriers. Taking into account all loci
associated with breast cancer risk in BRCA2 mutation carriers
from the current analysis, including the 6p24 locus, the 5% of the
BRCA2 mutation carriers at lowest risk were predicted to have
breast cancer risks by age 80 in the range of 21–47% compared to
83–100% for the 5% of mutation carriers at highest risk on the
basis of the combined SNP profile distribution. These results might
serve as a stimulus for prospective trials of the clinical utility of
such modifier panels.
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